{
    "clinical_study": {
        "@rank": "4746", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Active Comparator", 
                "description": "paracetamol marketed forumulation"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Active Comparator", 
                "description": "ibuprofen marketed formulation"
            }, 
            {
                "arm_group_label": "Arm 4", 
                "arm_group_type": "Experimental", 
                "description": "experimental paracetamol + caffeine formulation"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will compare a fast-absorbing paracetamol plus caffeine formula with placebo and\n      an over-the-counter dose of paracetamol and ibuprofen to treat episodic tension headache."
        }, 
        "brief_title": "Paracetamol With Caffeine to Treat Episodic Tension Type Headache", 
        "completion_date": {
            "#text": "March 2010", 
            "@type": "Actual"
        }, 
        "condition": "Headache, Tension-Type", 
        "condition_browse": {
            "mesh_term": [
                "Headache", 
                "Tension-Type Headache"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of episodic tension-type headache consistent with all of the following:\n\n               1. number of days with the condition is historically greater than or equal to two\n                  per month\n\n               2. onset of condition was greater than or equal to 12 months from Visit 1\n\n               3. age of onset was < 50 years\n\n               4. severity of headaches is historically at least moderate\n\n               5. duration of headaches is historically greater than or equal to four hours, if\n                  untreated\n\n               6. number of headache episodes was greater than or equal to 4 and less than or\n                  equal to 10 during each of the three months immediately prior to Visit 1\n\n               7. treatment of headache episodes with OTC analgesics has historically provided\n                  pain relief  in less than or equal to 2 hours\n\n        Exclusion Criteria:\n\n          -  Subject has chronic tension type headache, which is defined as headache on more than\n             15 days per month for 3 months.\n\n          -  If a migraine sufferer,subject averages more than one episode per month, is incapable\n             of differentiating between tension-type headaches and migraine headaches, and/or\n             requires regular or prophylactic use of migraine medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 23, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755702", 
            "org_study_id": "A2260597"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 4", 
                "description": "experimental paracetamol + caffeine formulation", 
                "intervention_name": "Experimental paracetamol + caffeine formulation", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "description": "ibuprofen marketed formulation", 
                "intervention_name": "ibuprofen marketed formulation", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "Paracetamol marketed formulation", 
                "intervention_name": "Paracetamol marketed formulation", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Ibuprofen", 
                "Caffeine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "caffeine", 
            "tension headache", 
            "paracetamol"
        ], 
        "lastchanged_date": "January 24, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Pembroke Pines", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33024"
                    }, 
                    "name": "University Clinical Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01104"
                    }, 
                    "name": "Springfield Neurology Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wellesley Hills", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02481"
                    }, 
                    "name": "MedVadis Research Corporation"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Success", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11042"
                    }, 
                    "name": "Biomedical Research Alliance of New York LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mount Vernon", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10550"
                    }, 
                    "name": "Elkind Headache Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Chester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10573"
                    }, 
                    "name": "International Research Service, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Jefferson Headache Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Study to Assess the Efficacy of Paracetamol Taken in Combination With Caffeine for the Treatment of Episodic Tension Type Headache", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "March 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "compare the efficacy of the rapidly-absorbed paracetamol + caffeine (RAPC) formula versus placebo in terms speed of onset as measured by time to perceptible first (i.e., \"a little\") using the pain relief/severity assessments diary cards.", 
            "measure": "headache relief", 
            "safety_issue": "No", 
            "time_frame": "Day 56 (Visit 3)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755702"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012", 
        "why_stopped": "Study was terminated due to unforeseen difficulties with subject recruitment.  No safety\n    issues were identified in the study with this new formulation."
    }
}